In clinical trials of neoadjuvant chemotherapy, younger women tend to have higher rates of pathologic complete response (pCR), which is linked with a better prognosis. New research, however, finds no difference in pCR in a range of age groups, and similar rates of downstaging in the breast and axilla.
To examine the impact of age on pCR and downstaging, Francys Verdial, MD, MPH—who, at the time of the research, was a fellow at Memorial Sloan Kettering Cancer Center (MSKCC) in New York